This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 and MutSigCV v0.9 merged result was used to generate the results found in this report.
-
Working with individual set: HNSC-TP
-
Number of patients in set: 306
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:HNSC-TP.final_analysis_set.maf
-
Significantly mutated genes (q ≤ 0.1): 39
-
Mutations seen in COSMIC: 485
-
Significantly mutated genes in COSMIC territory: 9
-
Significantly mutated genesets: 67
-
Read 306 MAFs of type "Broad"
-
Total number of mutations in input MAFs: 74008
-
After removing 10 mutations outside chr1-24: 73998
-
After removing 5555 noncoding mutations: 68443
-
After collapsing adjacent/redundant mutations: 58338
-
Number of mutations before filtering: 58338
-
After removing 1109 mutations outside gene set: 57229
-
After removing 56 mutations outside category set: 57173
Table 1. Get Full Table Table representing breakdown of mutations by type.
| type | count |
|---|---|
| Frame_Shift_Del | 1364 |
| Frame_Shift_Ins | 636 |
| In_Frame_Del | 433 |
| In_Frame_Ins | 83 |
| Missense_Mutation | 36408 |
| Nonsense_Mutation | 2886 |
| Nonstop_Mutation | 53 |
| Silent | 14249 |
| Splice_Site | 960 |
| Translation_Start_Site | 101 |
| Total | 57173 |
Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.
| category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
|---|---|---|---|---|---|---|
| *CpG->T | 5999 | 498919062 | 0.000012 | 12 | 2.5 | 2.1 |
| *Cp(A/C/T)->T | 9133 | 4084447193 | 2.2e-06 | 2.2 | 0.47 | 1.7 |
| C->(G/A) | 14223 | 4583366255 | 3.1e-06 | 3.1 | 0.65 | 4.8 |
| A->mut | 7136 | 4404728973 | 1.6e-06 | 1.6 | 0.34 | 3.9 |
| indel+null | 6379 | 8988095228 | 7.1e-07 | 0.71 | 0.15 | NaN |
| double_null | 54 | 8988095228 | 6e-09 | 0.006 | 0.0013 | NaN |
| Total | 42924 | 8988095228 | 4.8e-06 | 4.8 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).
Figure 1.
Figure 2. Patients counts and rates file used to generate this plot: HNSC-TP.patients.counts_and_rates.txt
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Figure 3. Get High-res Image SNV Mutation rate lego plot for entire set. Each bin is normalized by base coverage for that bin. Colors represent the six SNV types on the upper right. The three-base context for each mutation is labeled in the 4x4 legend on the lower right. The fractional breakdown of SNV counts is shown in the pie chart on the upper left. If this figure is blank, not enough information was provided in the MAF to generate it.
Figure 4. Get High-res Image SNV Mutation rate lego plots for 4 slices of mutation allele fraction (0<=AF<0.1, 0.1<=AF<0.25, 0.25<=AF<0.5, & 0.5<=AF) . The color code and three-base context legends are the same as the previous figure. If this figure is blank, not enough information was provided in the MAF to generate it.
Figure 5. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->T
-
n2 = number of nonsilent mutations of type: *Cp(A/C/T)->T
-
n3 = number of nonsilent mutations of type: C->(G/A)
-
n4 = number of nonsilent mutations of type: A->mut
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene
-
p_joint = p-value for clustering + conservation
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 39. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).
| rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_clust | p_cons | p_joint | p_cv | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | POLDIP2 | polymerase (DNA-directed), delta interacting protein 2 | 259479 | 6 | 6 | 2 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| 2 | NSD1 | nuclear receptor binding SET domain protein 1 | 2490988 | 36 | 33 | 36 | 1 | 0 | 2 | 8 | 4 | 20 | 2 | 0.0051 | 0.041 | 0.007 | 0 | 0 | 0 |
| 3 | NUDT11 | nudix (nucleoside diphosphate linked moiety X)-type motif 11 | 123243 | 6 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0.99 | 0 | 1 | 0 | 0 |
| 4 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 1003706 | 65 | 64 | 24 | 0 | 1 | 40 | 6 | 17 | 1 | 0 | 0 | 0.000073 | 0 | 5e-15 | 0 | 0 |
| 5 | CDKN2A | cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) | 255389 | 66 | 66 | 32 | 0 | 2 | 2 | 2 | 6 | 53 | 1 | 0 | 0 | 0 | 6e-15 | 0 | 0 |
| 6 | HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | 198292 | 11 | 10 | 6 | 0 | 2 | 2 | 6 | 1 | 0 | 0 | 0 | 0.00082 | 0 | 5.6e-07 | 0 | 0 |
| 7 | TP53 | tumor protein p53 | 375773 | 246 | 214 | 153 | 5 | 41 | 27 | 39 | 40 | 92 | 7 | 0 | 0 | 0 | 2.4e-15 | 0 | 0 |
| 8 | NFE2L2 | nuclear factor (erythroid-derived 2)-like 2 | 546479 | 18 | 17 | 13 | 0 | 0 | 4 | 10 | 4 | 0 | 0 | 0 | 2e-07 | 0 | 5.3e-08 | 0 | 0 |
| 9 | NOTCH1 | Notch homolog 1, translocation-associated (Drosophila) | 1904576 | 64 | 59 | 64 | 5 | 11 | 10 | 10 | 6 | 27 | 0 | 0.00079 | 0.5 | 0.002 | 1.6e-15 | 1.1e-16 | 2.2e-13 |
| 10 | FAT1 | FAT tumor suppressor homolog 1 (Drosophila) | 4166666 | 80 | 72 | 80 | 2 | 1 | 5 | 7 | 6 | 53 | 8 | 0.27 | 0.012 | 0.031 | 1e-15 | 1.2e-15 | 2.2e-12 |
| 11 | CASP8 | caspase 8, apoptosis-related cysteine peptidase | 533487 | 27 | 27 | 24 | 0 | 1 | 4 | 2 | 5 | 15 | 0 | 0.49 | 0.015 | 0.078 | 3.3e-15 | 9.7e-15 | 1.6e-11 |
| 12 | MLL2 | myeloid/lymphoid or mixed-lineage leukemia 2 | 4343439 | 58 | 56 | 58 | 3 | 4 | 7 | 7 | 2 | 35 | 3 | 0.31 | 0.15 | 0.21 | 4.8e-15 | 3.6e-14 | 5.4e-11 |
| 13 | JUB | jub, ajuba homolog (Xenopus laevis) | 357659 | 19 | 18 | 19 | 1 | 1 | 2 | 0 | 2 | 14 | 0 | 0.19 | 0.33 | 0.28 | 7.9e-15 | 7.5e-14 | 1e-10 |
| 14 | FBXW7 | F-box and WD repeat domain containing 7 | 757876 | 16 | 15 | 14 | 1 | 2 | 2 | 5 | 3 | 4 | 0 | 3.2e-06 | 0.58 | 0.000012 | 1.2e-07 | 4e-11 | 5.2e-08 |
| 15 | EPHA2 | EPH receptor A2 | 868017 | 16 | 14 | 15 | 0 | 3 | 0 | 1 | 1 | 10 | 1 | 0.1 | 0.23 | 0.085 | 1.6e-10 | 3.6e-10 | 4.4e-07 |
| 16 | ZNF750 | zinc finger protein 750 | 666533 | 15 | 13 | 14 | 1 | 1 | 2 | 2 | 2 | 8 | 0 | 0.00053 | 0.0097 | 4e-05 | 5.5e-07 | 5.6e-10 | 6.3e-07 |
| 17 | FLG | filaggrin | 3674091 | 59 | 48 | 59 | 9 | 8 | 12 | 25 | 6 | 7 | 1 | 0.014 | 0.22 | 0.017 | 1.9e-09 | 7.8e-10 | 8.3e-07 |
| 18 | B2M | beta-2-microglobulin | 113810 | 7 | 7 | 6 | 0 | 0 | 1 | 1 | 1 | 4 | 0 | 0.37 | 0.21 | 0.44 | 2e-09 | 1.9e-08 | 0.000019 |
| 19 | HLA-A | major histocompatibility complex, class I, A | 335447 | 14 | 14 | 9 | 4 | 0 | 0 | 0 | 6 | 8 | 0 | 0.0014 | 0.64 | 0.0035 | 7.7e-07 | 5.6e-08 | 0.000053 |
| 20 | EP300 | E1A binding protein p300 | 2248955 | 25 | 25 | 22 | 1 | 3 | 7 | 4 | 5 | 6 | 0 | 0.0018 | 0.11 | 0.0024 | 4.6e-06 | 2.1e-07 | 0.00019 |
| 21 | IL32 | interleukin 32 | 162670 | 4 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0.000023 | 0.9 | 0.0002 | 0.000064 | 2.4e-07 | 0.00021 |
| 22 | RHOA | ras homolog gene family, member A | 182942 | 4 | 4 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 1.2e-06 | 0.058 | 2.2e-06 | 0.025 | 9.7e-07 | 0.00079 |
| 23 | CTCF | CCCTC-binding factor (zinc finger protein) | 679423 | 13 | 11 | 13 | 1 | 1 | 2 | 5 | 0 | 5 | 0 | 0.026 | 0.22 | 0.035 | 5.8e-06 | 3.3e-06 | 0.0026 |
| 24 | RB1 | retinoblastoma 1 (including osteosarcoma) | 790351 | 10 | 10 | 10 | 2 | 0 | 1 | 1 | 0 | 8 | 0 | 0.57 | 0.13 | 0.45 | 1.3e-06 | 9.1e-06 | 0.0068 |
| 25 | CSMD3 | CUB and Sushi multiple domains 3 | 3506307 | 88 | 70 | 87 | 17 | 6 | 15 | 35 | 18 | 13 | 1 | 0.51 | 0.71 | 0.57 | 1.2e-06 | 1e-05 | 0.0075 |
| 26 | TGFBR2 | transforming growth factor, beta receptor II (70/80kDa) | 526462 | 11 | 10 | 9 | 1 | 1 | 1 | 0 | 2 | 7 | 0 | 0.37 | 0.55 | 0.5 | 1.7e-06 | 0.000013 | 0.0091 |
| 27 | NECAB1 | N-terminal EF-hand calcium binding protein 1 | 176105 | 6 | 6 | 6 | 2 | 0 | 0 | 2 | 0 | 3 | 1 | 0.81 | 0.89 | 1 | 1.3e-06 | 0.000019 | 0.013 |
| 28 | MAPK1 | mitogen-activated protein kinase 1 | 303224 | 4 | 4 | 1 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0.000067 | 0.22 | 0.00022 | 0.0095 | 0.000029 | 0.019 |
| 29 | PLSCR1 | phospholipid scramblase 1 | 302255 | 5 | 5 | 4 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0.0043 | 0.96 | 0.01 | 0.00031 | 0.000044 | 0.027 |
| 30 | CNPY3 | canopy 3 homolog (zebrafish) | 204182 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0.00012 | 0.64 | 0.00076 | 0.006 | 6e-05 | 0.036 |
| 31 | EPB41L3 | erythrocyte membrane protein band 4.1-like 3 | 1022950 | 16 | 16 | 16 | 5 | 3 | 0 | 6 | 4 | 3 | 0 | 0.0099 | 0.94 | 0.023 | 0.0002 | 0.000061 | 0.036 |
| 32 | RAC1 | ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | 189570 | 10 | 9 | 8 | 0 | 2 | 3 | 2 | 3 | 0 | 0 | 0.4 | 0.3 | 0.34 | 0.000015 | 0.000067 | 0.038 |
| 33 | RANGAP1 | Ran GTPase activating protein 1 | 514178 | 4 | 4 | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 1.4e-06 | 0.94 | 6.2e-06 | 1 | 0.000081 | 0.044 |
| 34 | ZCCHC3 | zinc finger, CCHC domain containing 3 | 214314 | 5 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 1 | 6.4e-06 | 1 | 0.000083 | 0.044 |
| 35 | CUL3 | cullin 3 | 703996 | 10 | 10 | 10 | 1 | 1 | 1 | 3 | 2 | 3 | 0 | 0.077 | 0.54 | 0.12 | 0.000063 | 0.000099 | 0.051 |
Figure S1. This figure depicts the distribution of mutations and mutation types across the POLDIP2 significant gene.
Figure S2. This figure depicts the distribution of mutations and mutation types across the NSD1 significant gene.
Figure S3. This figure depicts the distribution of mutations and mutation types across the NUDT11 significant gene.
Figure S4. This figure depicts the distribution of mutations and mutation types across the PIK3CA significant gene.
Figure S5. This figure depicts the distribution of mutations and mutation types across the CDKN2A significant gene.
Figure S6. This figure depicts the distribution of mutations and mutation types across the HRAS significant gene.
Figure S7. This figure depicts the distribution of mutations and mutation types across the TP53 significant gene.
Figure S8. This figure depicts the distribution of mutations and mutation types across the NFE2L2 significant gene.
Figure S9. This figure depicts the distribution of mutations and mutation types across the NOTCH1 significant gene.
Figure S10. This figure depicts the distribution of mutations and mutation types across the FAT1 significant gene.
Figure S11. This figure depicts the distribution of mutations and mutation types across the MLL2 significant gene.
Figure S12. This figure depicts the distribution of mutations and mutation types across the JUB significant gene.
Figure S13. This figure depicts the distribution of mutations and mutation types across the FBXW7 significant gene.
Figure S14. This figure depicts the distribution of mutations and mutation types across the EPHA2 significant gene.
Figure S15. This figure depicts the distribution of mutations and mutation types across the ZNF750 significant gene.
Figure S16. This figure depicts the distribution of mutations and mutation types across the FLG significant gene.
Figure S17. This figure depicts the distribution of mutations and mutation types across the B2M significant gene.
Figure S18. This figure depicts the distribution of mutations and mutation types across the HLA-A significant gene.
Figure S19. This figure depicts the distribution of mutations and mutation types across the EP300 significant gene.
Figure S20. This figure depicts the distribution of mutations and mutation types across the IL32 significant gene.
Figure S21. This figure depicts the distribution of mutations and mutation types across the RHOA significant gene.
Figure S22. This figure depicts the distribution of mutations and mutation types across the CTCF significant gene.
Figure S23. This figure depicts the distribution of mutations and mutation types across the RB1 significant gene.
Figure S24. This figure depicts the distribution of mutations and mutation types across the CSMD3 significant gene.
Figure S25. This figure depicts the distribution of mutations and mutation types across the TGFBR2 significant gene.
Figure S26. This figure depicts the distribution of mutations and mutation types across the NECAB1 significant gene.
Figure S27. This figure depicts the distribution of mutations and mutation types across the MAPK1 significant gene.
Figure S28. This figure depicts the distribution of mutations and mutation types across the PLSCR1 significant gene.
Figure S29. This figure depicts the distribution of mutations and mutation types across the CNPY3 significant gene.
Figure S30. This figure depicts the distribution of mutations and mutation types across the EPB41L3 significant gene.
Figure S31. This figure depicts the distribution of mutations and mutation types across the RAC1 significant gene.
Figure S32. This figure depicts the distribution of mutations and mutation types across the RANGAP1 significant gene.
Figure S33. This figure depicts the distribution of mutations and mutation types across the ZCCHC3 significant gene.
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 9. Number of genes displayed: 10
| rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TP53 | tumor protein p53 | 246 | 356 | 224 | 108936 | 45925 | 0 | 0 |
| 2 | CDKN2A | cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) | 66 | 332 | 64 | 101592 | 2930 | 0 | 0 |
| 3 | HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | 11 | 19 | 11 | 5814 | 2979 | 1.7e-13 | 2.5e-10 |
| 4 | FBXW7 | F-box and WD repeat domain containing 7 | 16 | 91 | 10 | 27846 | 183 | 7.2e-13 | 8.1e-10 |
| 5 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 65 | 220 | 55 | 67320 | 26369 | 1.4e-12 | 1.3e-09 |
| 6 | CHEK2 | CHK2 checkpoint homolog (S. pombe) | 9 | 2 | 4 | 612 | 4 | 3e-12 | 2.3e-09 |
| 7 | PIK3R1 | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 6 | 33 | 4 | 10098 | 3 | 2.2e-07 | 0.00014 |
| 8 | PTPN14 | protein tyrosine phosphatase, non-receptor type 14 | 13 | 3 | 2 | 918 | 2 | 9.6e-06 | 0.0054 |
| 9 | SCN9A | sodium channel, voltage-gated, type IX, alpha subunit | 10 | 4 | 2 | 1224 | 2 | 0.000017 | 0.0085 |
| 10 | PTCH1 | patched homolog 1 (Drosophila) | 11 | 256 | 4 | 78336 | 5 | 0.00061 | 0.19 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
Table 5. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 67. Number of genesets displayed: 10
| rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HSA04115_P53_SIGNALING_PATHWAY | Genes involved in p53 signaling pathway | APAF1, ATM, ATR, BAI1, BAX, BBC3, BID, CASP3, CASP8, CASP9, CCNB1, CCNB2, CCNB3, CCND1, CCND2, CCND3, CCNE1, CCNE2, CCNG1, CCNG2, CD82, CDC2, CDK2, CDK4, CDK6, CDKN1A, CDKN2A, CHEK1, CHEK2, CYCS, DDB2, EI24, FAS, GADD45A, GADD45B, GADD45G, GTSE1, IGF1, IGFBP3, LRDD, MDM2, MDM4, P53AIP1, PERP, PMAIP1, PPM1D, PTEN, RCHY1, RFWD2, RPRM, RRM2, RRM2B, SCOTIN, SERPINB5, SERPINE1, SESN1, SESN2, SESN3, SFN, SIAH1, STEAP3, THBS1, TNFRSF10B, TP53, TP53I3, TP73, TSC2, ZMAT3 | 65 | APAF1(9), ATM(9), ATR(19), BAI1(4), BAX(1), BID(2), CASP3(1), CASP8(27), CCNB1(3), CCNB3(5), CCND1(2), CCNE1(3), CCNE2(3), CCNG1(1), CCNG2(2), CDK4(4), CDK6(1), CDKN2A(66), CHEK1(1), CHEK2(9), DDB2(2), EI24(1), FAS(1), GADD45G(1), GTSE1(4), IGFBP3(1), LRDD(3), MDM2(2), MDM4(1), PERP(1), PMAIP1(2), PPM1D(2), PTEN(6), RCHY1(1), RFWD2(1), RRM2(1), RRM2B(1), SERPINE1(4), SESN3(1), SFN(5), SIAH1(1), STEAP3(2), THBS1(7), TNFRSF10B(1), TP53(246), TSC2(3) | 29795051 | 473 | 249 | 340 | 38 | 57 | 62 | 73 | 90 | 183 | 8 | <1.00e-15 | <1.00e-15 | <6.16e-14 |
| 2 | G2PATHWAY | Activated Cdc2-cyclin B kinase regulates the G2/M transition; DNA damage stimulates the DNA-PK/ATM/ATR kinases, which inactivate Cdc2. | ATM, ATR, BRCA1, CCNB1, CDC2, CDC25A, CDC25B, CDC25C, CDC34, CDKN1A, CDKN2D, CHEK1, CHEK2, EP300, GADD45A, MDM2, MYT1, PLK, PRKDC, RPS6KA1, TP53, WEE1, YWHAH, YWHAQ | 22 | ATM(9), ATR(19), BRCA1(9), CCNB1(3), CDC25B(3), CDC34(1), CHEK1(1), CHEK2(9), EP300(25), MDM2(2), MYT1(7), PRKDC(15), RPS6KA1(4), TP53(246), WEE1(1), YWHAH(1), YWHAQ(1) | 19102840 | 356 | 237 | 257 | 25 | 53 | 50 | 66 | 69 | 111 | 7 | 3.66e-15 | <1.00e-15 | <6.16e-14 |
| 3 | ATRBRCAPATHWAY | BRCA1 and 2 block cell cycle progression in response to DNA damage and promote double-stranded break repair; mutations induce breast cancer susceptibility. | ATM, ATR, BRCA1, BRCA2, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, HUS1, MRE11A, NBS1, RAD1, RAD17, RAD50, RAD51, RAD9A, TP53, TREX1 | 21 | ATM(9), ATR(19), BRCA1(9), BRCA2(11), CHEK1(1), CHEK2(9), FANCA(4), FANCC(2), FANCD2(3), FANCG(2), HUS1(2), MRE11A(1), RAD17(3), RAD50(5), RAD51(1), TP53(246), TREX1(2) | 20066645 | 329 | 233 | 233 | 20 | 47 | 50 | 56 | 65 | 104 | 7 | 1.93e-14 | <1.00e-15 | <6.16e-14 |
| 4 | G1PATHWAY | CDK4/6-cyclin D and CDK2-cyclin E phosphorylate Rb, which allows the transcription of genes needed for the G1/S cell cycle transition. | ABL1, ATM, ATR, CCNA1, CCND1, CCNE1, CDC2, CDC25A, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, DHFR, E2F1, GSK3B, HDAC1, MADH3, MADH4, RB1, SKP2, TFDP1, TGFB1, TGFB2, TGFB3, TP53 | 25 | ATM(9), ATR(19), CCNA1(4), CCND1(2), CCNE1(3), CDK4(4), CDK6(1), CDKN1B(2), CDKN2A(66), DHFR(3), GSK3B(1), RB1(10), SKP2(2), TFDP1(3), TGFB1(1), TGFB2(2), TP53(246) | 13736583 | 378 | 233 | 251 | 19 | 48 | 43 | 56 | 61 | 162 | 8 | <1.00e-15 | <1.00e-15 | <6.16e-14 |
| 5 | ST_JNK_MAPK_PATHWAY | JNKs are MAP kinases regulated by several levels of kinases (MAPKK, MAPKKK) and phosphorylate transcription factors and regulatory proteins. | AKT1, ATF2, CDC42, DLD, DUSP10, DUSP4, DUSP8, GAB1, GADD45A, GCK, IL1R1, JUN, MAP2K4, MAP2K5, MAP2K7, MAP3K1, MAP3K10, MAP3K11, MAP3K12, MAP3K13, MAP3K2, MAP3K3, MAP3K4, MAP3K5, MAP3K7, MAP3K7IP1, MAP3K7IP2, MAP3K9, MAPK10, MAPK7, MAPK8, MAPK9, MYEF2, NFATC3, NR2C2, PAPPA, SHC1, TP53, TRAF6, ZAK | 38 | AKT1(2), ATF2(1), CDC42(1), DUSP10(2), DUSP4(1), GAB1(2), GCK(2), IL1R1(2), MAP2K4(1), MAP2K5(2), MAP3K1(3), MAP3K10(4), MAP3K11(1), MAP3K12(6), MAP3K13(8), MAP3K3(1), MAP3K4(6), MAP3K5(5), MAP3K7(4), MAP3K9(3), MAPK10(3), MAPK7(1), MAPK8(4), MAPK9(4), MYEF2(3), NFATC3(6), NR2C2(1), PAPPA(9), SHC1(1), TP53(246), TRAF6(1), ZAK(2) | 22997165 | 338 | 232 | 245 | 30 | 52 | 50 | 70 | 53 | 106 | 7 | 3.57e-13 | <1.00e-15 | <6.16e-14 |
| 6 | RBPATHWAY | The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. | ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH | 12 | ATM(9), CDC25B(3), CDK4(4), CHEK1(1), MYT1(7), RB1(10), TP53(246), WEE1(1), YWHAH(1) | 7991690 | 282 | 226 | 189 | 12 | 44 | 33 | 49 | 46 | 103 | 7 | 3.11e-15 | <1.00e-15 | <6.16e-14 |
| 7 | P53HYPOXIAPATHWAY | Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. | ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 | 19 | ABCB1(11), AKT1(2), ATM(9), BAX(1), CPB2(3), CSNK1A1(1), FHL2(1), HIC1(1), HIF1A(2), IGFBP3(1), MAPK8(4), MDM2(2), NFKBIB(1), TP53(246) | 9472034 | 285 | 220 | 192 | 19 | 45 | 34 | 54 | 47 | 98 | 7 | 6.34e-13 | <1.00e-15 | <6.16e-14 |
| 8 | TERTPATHWAY | hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. | HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 | 7 | MAX(1), MYC(4), SP1(1), SP3(1), TP53(246) | 3219260 | 253 | 214 | 160 | 7 | 41 | 28 | 42 | 42 | 93 | 7 | <1.00e-15 | <1.00e-15 | <6.16e-14 |
| 9 | IGF1RPATHWAY | Insulin-like growth factor receptor IGF-1R promotes cell growth and inhibits apoptosis on binding of ligands IGF-1 and 2 via Ras activation and the AKT pathway. | AKT1, BAD, GRB2, HRAS, IGF1R, IRS1, MAP2K1, MAPK1, MAPK3, PIK3CA, PIK3R1, RAF1, SHC1, SOS1, YWHAH | 15 | AKT1(2), BAD(1), HRAS(11), IGF1R(7), IRS1(1), MAP2K1(4), MAPK1(4), PIK3CA(65), PIK3R1(6), RAF1(2), SHC1(1), SOS1(8), YWHAH(1) | 8655628 | 113 | 94 | 64 | 5 | 11 | 50 | 23 | 23 | 6 | 0 | 1.87e-11 | <1.00e-15 | <6.16e-14 |
| 10 | GCRPATHWAY | Corticosteroids activate the glucocorticoid receptor (GR), which inhibits NF-kB and activates Annexin-1, thus inhibiting the inflammatory response. | ADRB2, AKT1, ANXA1, CALM1, CALM2, CALM3, CRN, GNAS, GNB1, GNGT1, HSPCA, NFKB1, NOS3, NPPA, NR3C1, PIK3CA, PIK3R1, RELA, SYT1 | 17 | AKT1(2), ANXA1(1), CALM1(1), CALM3(1), GNAS(6), GNB1(2), NFKB1(2), NOS3(4), NPPA(1), NR3C1(5), PIK3CA(65), PIK3R1(6), RELA(1), SYT1(5) | 8161012 | 102 | 89 | 61 | 4 | 12 | 48 | 12 | 25 | 5 | 0 | 1.42e-10 | <1.00e-15 | <6.16e-14 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.